EC5026

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

EC5026 has the potential to relieve pain by stabilizing natural analgesic and anti-inflammatory mediators.?EC5026 (BPN-19186) is a first-in-class, small molecule that potently inhibits soluble Epoxide Hydrolase (sEH), a key regulatory enzyme involved in the metabolism of membrane fatty acids.?Inhibition of sEH treats pain by stabilizing natural analgesic and anti-inflammatory mediators.

EC5026 has the potential to relieve pain by stabilizing natural analgesic and anti-inflammatory mediators.?EC5026 (BPN-19186) is a first-in-class, small molecule that potently inhibits soluble Epoxide Hydrolase (sEH), a key regulatory enzyme involved in the metabolism of membrane fatty acids.?Inhibition of sEH treats pain by stabilizing natural analgesic and anti-inflammatory mediators.?sEH inhibitors developed by EicOsis have already shown efficacy for treating pain with no apparent adverse or addictive effects in laboratory animals and relieving naturally occurring pain in dogs, cats and horses.

BPN-19186

Others

Other Targets

sEH

——

——

1809885-32-2

405.39

C18H23F4N3O3

>98% (HPLC)

DMSO:250 mg/mL (616.69 mM)

O=C(NC1CCN(C([C@@H](C)CC)=O)CC1)NC2=CC=C(OC(F)(F)F)C(F)=C2

——

(-20℃)

With Ice Pack

≥ 2 years